Target Price | $5.27 |
Price | $2.21 |
Potential |
138.59%
register free of charge
|
Number of Estimates | 11 |
11 Analysts have issued a price target Maravai LifeSciences 2026 .
The average Maravai LifeSciences target price is $5.27.
This is
138.59%
register free of charge
$12.00
442.99%
register free of charge
$2.00
9.50%
register free of charge
|
|
A rating was issued by 15 analysts: 7 Analysts recommend Maravai LifeSciences to buy, 7 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Maravai LifeSciences stock has an average upside potential 2026 of
138.59%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 259.19 | 192.93 |
10.30% | 25.56% | |
EBITDA Margin | -2.40% | -8.05% |
115.53% | 235.99% | |
Net Margin | -57.52% | -47.83% |
30.06% | 16.84% |
15 Analysts have issued a sales forecast Maravai LifeSciences 2025 . The average Maravai LifeSciences sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Maravai LifeSciences EBITDA forecast 2025. The average Maravai LifeSciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Maravai LifeSciences Analysts have issued a net profit forecast 2025. The average Maravai LifeSciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.05 | -0.65 |
16.67% | 38.10% | |
P/E | negative | |
EV/Sales | 3.20 |
3 Analysts have issued a Maravai LifeSciences forecast for earnings per share. The average Maravai LifeSciences EPS is
This results in the following potential growth metrics and future valuations:
Maravai LifeSciences...
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
UBS |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Baird |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Dec 05 2024 |
Wolfe Research |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
Baird |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
Analyst Rating | Date |
---|---|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 25 2025 |
Locked
UBS:
Locked
➜
Locked
|
Mar 21 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Baird:
Locked
➜
Locked
|
Feb 26 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Dec 05 2024 |
Locked
Wolfe Research:
Locked
➜
Locked
|
Nov 14 2024 |
Locked
Baird:
Locked
➜
Locked
|
Nov 08 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.